Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 356 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Polyethylene glycol Clear all
Completed Phase 1 Interventional Results available

Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)

NCT00866307
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Prophylactic Cranial Irradiation, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
25
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Sep 5, 2026, 5:17 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00103285
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
3-Dimensional Conformal Radiation Therapy, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine Sulfate
Radiation · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 9 Years
Enrollment
5,377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2021
U.S. locations
210
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 5, 2026, 5:17 PM EDT
Completed No phase listed Observational

The Efficacy Side Effects and the Tolerance of Polyethylene Glycol 3350 as a Bowel Prep in Children

NCT01164410
View directory record Official record
Conditions
Colonoscopy
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
5 Years to 21 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Sep 5, 2026, 5:17 PM EDT
Recruiting Not applicable Interventional

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

NCT04199026
View directory record Official record
Conditions
Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma
Interventions
Doxorubicin, Doxorubicin Hydrochloride, Drug Delivery Microdevice, Everolimus, Ganitumab, Ifosfamide, Irinotecan, Pazopanib, Polyethylene Glycol, Temozolomide, Temsirolimus, Therapeutic Conventional Surgery, Vincristine
Drug · Device · Biological + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
10 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 5, 2026, 5:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Polyethylene Glycol Safety in Children

NCT05424757
View directory record Official record
Conditions
Polyethylene Glycols, Children, Only
Interventions
PEG 3350
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Years to 16 Years
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 5, 2026, 5:17 PM EDT
Completed Phase 4 Interventional

A Pilot Study of a New PEG3350 Dose Formulation For Use in Constipated Children

NCT00583609
View directory record Official record
Conditions
Constipation
Interventions
PEG3350
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
4 Years to 16 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Little Rock, Arkansas • Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 27, 2009 · Synced Sep 5, 2026, 5:17 PM EDT
Completed Phase 1 Interventional

Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas

NCT02120807
View directory record Official record
Conditions
Stage IV Lung Adenocarcinoma
Interventions
Certolizumab, cisplatin, pemetrexed
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 5, 2026, 5:17 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT02938520
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 5, 2026, 5:17 PM EDT
Completed Phase 3 Interventional Results available

Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease

NCT00333788
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab pegol (CDP870)
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
19
States / cities
Gainesville, Florida • Atlanta, Georgia • Chicago, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 5, 2026, 5:17 PM EDT
Completed Phase 1 Interventional

ADI-PEG in Patients With Metastatic Melanoma

NCT00029900
View directory record Official record
Conditions
Melanoma, Neoplasm Metastasis
Interventions
ADI PEG
Drug
Lead sponsor
FDA Office of Orphan Products Development
Federal
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 5, 2026, 5:17 PM EDT
Completed Not applicable Interventional

Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2

NCT00002017
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin-2, Polyethylene Glycolated
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 5, 2026, 5:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Microbial Colonization in Three Dimensional (3D) Printed Orthodontic Clear Aligners

NCT07143370
View directory record Official record
Conditions
Orthodontic Aligner, Microbial Colonization
Interventions
Thermoformed clear aligner, 3D printed clear aligner TC-85, 3D printed clear aligner TA-28
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 5, 2026, 5:17 PM EDT
Completed No phase listed Observational Results available

Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)

NCT03257254
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
Varithena
Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Timeline
2017 – 2020
U.S. locations
13
States / cities
Palo Alto, California • Sacramento, California • Darien, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Sep 5, 2026, 5:17 PM EDT
Completed Phase 3 Interventional Results available

Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)

NCT01374971
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol (CZP), Arthroscopic synovial tissue biopsy
Drug · Procedure
Lead sponsor
Nathan Wei, MD, FACP, FACR:
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Sep 5, 2026, 5:17 PM EDT
Completed Phase 4 Interventional Results available

Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia

NCT01147341
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Cimzia, Placebo
Drug
Lead sponsor
Michael Schiff, MD
Individual
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 5, 2026, 5:17 PM EDT
Not listed Phase 4 Interventional

Does Clinical Response Correlate With Serum Certolizumab Levels?

NCT02597829
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab Pegol
Drug
Lead sponsor
Shafran Gastroenterology Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Sep 5, 2026, 5:17 PM EDT
Completed Phase 3 Interventional

The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients

NCT01213017
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
certolizumab pegol
Drug
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Aventura, Florida • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Sep 5, 2026, 5:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Morning-Only 4 L PEG vs Split Dose Prep for Afternoon Colonoscopies, Endoscopist-Blinded Prospective Study

NCT02643316
View directory record Official record
Conditions
Colonoscopy
Interventions
Same day 4 L preparation (Polyethylene Glycol), Split dose 4 L preparation (Polyethylene Glycol)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Sep 5, 2026, 5:17 PM EDT
Completed Phase 1 Interventional Results available

A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers

NCT02154425
View directory record Official record
Conditions
Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis
Interventions
Breast milk sampling, Certolizumab Pegol
Procedure · Biological
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Sep 5, 2026, 5:17 PM EDT
Completed Not applicable Interventional Results available

Instylla HES Hypervascular Tumor Pivotal Study

NCT04523350
View directory record Official record
Conditions
Hypervascular Tumors
Interventions
Instylla HES, TAE or cTACE
Device · Other
Lead sponsor
Instylla, Inc.
Industry
Eligibility
22 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Irvine, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 5, 2026, 5:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tear Lipid Layer Thickness Changes With Use of Emollient and Non-Emollient Eye Drops

NCT03706443
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca, Lacrimal Apparatus Diseases, Keratoconjunctivitis, Eye Diseases, Keratitis, Corneal Disease, Ophthalmic Solution
Interventions
Systane Complete, Systane Ultra
Other
Lead sponsor
Ohio State University
Other
Eligibility
30 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Sep 5, 2026, 5:17 PM EDT
Active, not recruiting Not applicable Interventional

Impact of Chewing Gum on Bowel Preparation in Patients Undergoing Colonoscopy

NCT07320989
View directory record Official record
Conditions
Colon Cancer Screening
Interventions
Chewing Sugar-Free Gum During Bowel Preparation, Standard Bowel Prep (2L PEG-ELP), Standard Bowel Prep
Behavioral · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
45 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 5, 2026, 5:17 PM EDT
Completed Phase 3 Interventional Results available

A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

NCT02615691
View directory record Official record
Conditions
Hemophilia A
Interventions
PEGylated Recombinant Factor VIII, ITI
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 5 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
20
States / cities
Phoenix, Arizona • Cupertino, California • Oakland, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 5, 2026, 5:17 PM EDT
Completed Phase 1 Interventional Results available

A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis

NCT04740814
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab pegol
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 69 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
14
States / cities
Phoenix, Arizona • Covina, California • Upland, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2024 · Synced Sep 5, 2026, 5:17 PM EDT